Download Files:
Products Details
Product Description
– JTS-653 is a highly potent and selective transient receptor potential vanilloid 1 (TRPV1) antagonist in vitro and in vivo. JTS-653 attenuates chronic pain refractory to non-steroidal anti-inflammatory agents[1].
Web ID
– HY-19589
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C23H21F3N4O4
References
– [1]Yoshihiro Kitagawa, et al. Pharmacological characterization of (3S)-3-(hydroxymethyl)-4-(5-methylpyridin-2-yl)-N-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]-3,4-dihydro-2H-benzo[b][1,4]oxazine-8-carboxamide (JTS-653), a novel transient receptor potential vanilloid 1 antagonist. J Pharmacol Exp Ther. 2012 Aug;342(2):520-8.|[2]Yoshihiro Kitagawa, et al. Orally administered selective TRPV1 antagonist, JTS-653, attenuates chronic pain refractory to non-steroidal anti-inflammatory drugs in rats and mice including post-herpetic pain. J Pharmacol Sci. 2013;122(2):128-37.
CAS Number
– 942614-99-5
Molecular Weight
– 474.43
SMILES
– OC[C@@H]1N(C(N=C2)=CC=C2C)C3=CC=CC(C(NC(C=C4)=CN=C4OCC(F)(F)F)=O)=C3OC1
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Neurological Disease
Solubility
– 10 mM in DMSO
Target
– TRP Channel
Isoform
– TRPV
Pathway
– Membrane Transporter/Ion Channel;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
